Dupuy-Gorce A M, Desmarais E, Vigneron S, Buresi C, Nicaud V, Evans A, Luc G, Arveiler D, Marqués-Vidal P, Cambien F, Tiret L, Crastes de Paulet A, Roizés G
Laboratoire de Biochimie A, Institut de Biologie, Montpellier, France.
Clin Genet. 1996 Oct;50(4):191-8. doi: 10.1111/j.1399-0004.1996.tb02624.x.
Two investigations were undertaken to analyze the 3' region of the apolipoprotein AII (Apo AII) gene in patients with myocardial infarction (MI) and controls. Previous studies have suggested that a MspI polymorphism in this gene may be associated with hypertriglyceridaemia, high levels of HDL cholesterol and Apo AII. To verify this hypothesis, the distribution of MspI genotypes and their possible associations with several plasma lipid variables were studied in 882 subjects (411 cases with MI and 471 controls) from the ECTIM study. There were no differences in genotype and allele frequencies between cases and controls, and no differences in lipid variable levels in controls carrying the less frequent MspI allele vs other controls. Using single-strand conformation polymorphism (SSCP) analysis, we detected a new polymorphism which caused by a C-to-T transition located in the third intron near the splice junction site (acceptor). This polymorphism modifies a Bst N1 restriction site. The ECTIM population was screened for this new marker, and no significant associations with MI and plasma lipid levels were found. Our results suggest that these two variants located in the coding region of the Apo AII gene are unlikely to contribute significantly to the level of plasma lipid variables and the risk of coronary heart disease (CHD) in the European population.
开展了两项调查,以分析心肌梗死(MI)患者和对照组中载脂蛋白AII(Apo AII)基因的3'区域。先前的研究表明,该基因中的MspI多态性可能与高甘油三酯血症、高水平的高密度脂蛋白胆固醇和Apo AII有关。为了验证这一假设,在ECTIM研究的882名受试者(411例MI患者和471名对照)中研究了MspI基因型的分布及其与几种血浆脂质变量的可能关联。病例组和对照组之间的基因型和等位基因频率没有差异,携带较罕见MspI等位基因的对照组与其他对照组的脂质变量水平也没有差异。使用单链构象多态性(SSCP)分析,我们检测到一个新的多态性,它是由位于剪接连接位点(受体)附近第三个内含子中的C到T转换引起的。这种多态性改变了一个Bst N1限制性位点。对ECTIM人群进行了这种新标记的筛查,未发现与MI和血浆脂质水平有显著关联。我们的结果表明,位于Apo AII基因编码区的这两个变体不太可能对欧洲人群的血浆脂质变量水平和冠心病(CHD)风险有显著影响。